HIND (Vyome Holdings Inc.) Sof foyda

Vyome Holdings Inc biznesi doimiy tadqiqot va ishlanmalar (R&D) xarajatlariga tayanadi, bu esa hamkorlar orqali dori vositalari bozorga chiqarilganda ortiqcha foydani ta'minlaydi. GURU.Markets servisi tomonidan taqdim etilgan kompaniyaning umumiy sof foydasi -0.01 joriy ko'rsatkichni ifodalovchi tendentsiyani namoyish etmoqda. Masshtablash modeli moddiy xarajatlari past bo'lgan patentlarga asoslangan, joriy rivojlanish vektori esa birlashmalar va semizlikni davolash vositalari taqsimotini optimallashtirishga qaratilgan.

HIND (Vyome Holdings Inc) Sof foyda tarixi 16.08.2025dan 01.11.2026gacha

Vyome Holdings (HIND) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Vyome Therapeutics|HIND - Tahlilchilar konsensus prognozi
- biznesning bozor baholash ko'rsatkichlari:
Bozor kapitallashuvi Vyome Therapeutics|HIND - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Aksiyaning buxgalteriya qiymati Vyome Holdings|HIND - Balans kapitallashuvi|Balans qiymatiga nisbatan bozor kapitallashuvi reshapelifesciences.com|HIND - Kompaniyaning jami aktivlari
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Vyome Holdings Inc|HIND - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Vyome Holdings Inc.|HIND - Kompaniyaning umumiy qarzi|Balans kapitallashuviga qarzlar Vyome Therapeutics|HIND - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Vyome Holdings|Shoshilinch likvidlik reshapelifesciences.com
- sof daromad va qiymat multiplikatorlari ko'rsatkichlari:
HIND - Sof daromad
Kompaniyaning jamlanma tahlili:Vyome Holdings Inc

Vyome Holdings Inc (HIND) kompaniyasining semizlik va akneni davolash segmentidagi narxlarni belgilash kuchi kompaniyaning tijorat natijalarida aks etgan moliyaviy barqarorlik bilan bevosita bog'liqdir. Ushbu ko'rsatkich barcha xarajatlar chegirilgan holdagi sof kunlik pul oqimini ifodalaydi, bu esa investorlarga haqiqiy daromadlarni matematik tahlil qilish orqali aktivning adolatli qiymatini aniqlash va bozorning tez-tez uchraydigan tebranishlari sharoitida haddan tashqari ko'p to'lov qilishdan qochish imkonini beradi.

Asosiy raqobatchilar

Sof daromad argenx BVBA|BNTX (BioNTech SE) - Sof foyda|Sof foyda Abivax Pharma|Sof daromad ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Yakuniy foyda|Sof foyda IMVT (Immunovant Corp)|Sof moliyaviy natija Kiniksa Corp (KNSA)|GRFS - Kompaniyaning sof foydasi|adaptivebiotech.com (ADPT) - Sof daromad|Celldex Therapeutics, Inc. (CLDX) - Kompaniyaning sof foydasi|Sof daromad Aurinia Pharmaceuticals Inc|Sof daromad BCRX|Sof foyda Vera Corp|Kompaniyaning sof foydasi Dianthus Therapeutics (DNTH)|pharvaris.com - Kompaniya foydasi|Sof foyda ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Kompaniyaning sof daromadi|PGEN: Sof daromad|PHAR: Kompaniyaning sof foydasi|NKTR (Nektar Therapeutics) - Sof daromad|Kompaniyaning sof daromadi upstreambio.com (UPB)|Kompaniyaning sof foydasi Zenas Biopharma|Kompaniyaning sof daromadi Immunome Inc IMNM|Kompaniyaning sof foydasi Gossamer Corp (GOSS)|Sof daromad KalVista Corp KALV|Sof foyda SEPN (Septerna Inc)|pieris.com (PVLA) - Kompaniyaning sof daromadi|SVRA: Sof daromad|Yakuniy foyda RIGL (Rigel Pharma)|ANAB: Sof foyda|Astria Corp - Yakuniy foyda|Kompaniyaning sof foydasi enGene Holdings Inc.|Kompaniyaning sof daromadi rapt.com RAPT|Kompaniyaning sof foydasi Aerovate Therapeutics Inc (JBIO)|Kompaniyaning sof foydasi ACRS (Aclaris Therapeutics Inc.)|Sof foyda KYTX (Kyverna)|TLSA: Kompaniya foydasi|Cabaletta Bio, Inc. - Sof foyda|Sof moliyaviy natija ventyxbio.com VTYX|Theratechnologies (THTX) - Kompaniyaning sof foydasi|Kompaniya foydasi AVTX|ELDN (Eledon) - Sof foyda|AGEN - Yillik sof foyda|Kompaniyaning sof foydasi Climb Bio Inc (CLYM)|Sof moliyaviy natija zurabio.com|aTyr Pharma - Sof daromad|Yakuniy foyda ADAG|Ikena Oncology, Inc. - Sof foyda|Sof moliyaviy natija Shattuck Labs, Inc. STTK|equilliumbio.com (EQ) - Kompaniyaning sof foydasi|Kompaniya foydasi CNTB|IMUX (Immunic Therapeutics) - Sof foyda|Sof daromad Atara Biotherapeutics Inc (ATRA)|Sof foyda IFRX|XFOR (X4 Pharmaceuticals, Inc) - Yakuniy foyda|Sof foyda ACET (Adicet Bio, Inc.)|Sof moliyaviy natija Celularity Inc (CELU)|INMB - Kompaniyaning sof foydasi|BRNS (Barinthus Biotherapeutics PLC) - Kompaniya foydasi|KZR: Sof foyda|Kompaniya foydasi SABS|Kompaniyaning sof foydasi Akari Therapeutics|Enlivex Therapeutics, Ltd. - Soliqdan keyingi foyda|Sof foyda QTTB|GOVX (GeoVax Labs) - Yakuniy foyda|Sof foyda EDSA (Edesa)|Sof foyda iBio Corporation IBIO|CARM - Kompaniyaning sof foydasi|Yakuniy foyda XTLB (xtlbio.com)|boltbio.com (BOLT) - Kompaniyaning sof foydasi|Sof daromad HCW Biologics|APVO (Aptevo Therapeutics, Inc.) - Sof foyda|Sof foyda aimimmuno.com|Sof daromad ADTX (Aditxt)|GRI (gribio.com) - Yakuniy foyda|Sof foyda XRTX (XORTX Therapeutics)|Sof moliyaviy natija Revelation Biosciences Inc (REVB)|INDP - Kompaniyaning sof foydasi|BiondVax Pharmaceuticals (SCNI) - Sof daromad|calcimedica.com (CALI) - Kompaniyaning sof foydasi|Sof daromad Affimed N.V.|Sof daromad ALLK|Sof foyda HOOKIPA|Kompaniyaning sof foydasi IGM Biosciences, Inc. (IGMS)|iTeos Pharma - Kompaniya foydasi|Sof foyda OCEA (Ocean Biomedical, Inc.)|tcbiopharm.com (TCBP) - Kompaniyaning sof daromadi|THRD: Sof daromad